Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
SHR-A1201
(trastuzumab emtansine biosimilar) /
Jiangsu Hengrui Pharma
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
||
||||||||
SHR-A1201
(trastuzumab emtansine biosimilar) /
Jiangsu Hengrui Pharma
P1 data, PK/PD data, Journal, Metastases:
Safety, tolerability, pharmacokinetics and immunogenicity of an antibody-drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study.
(Pubmed Central) - May 15, 2023
SHR-A1201 was well tolerated and safe in patients with advanced HER2-positive breast cancer. The pharmacokinetics parameters showed a linear trend, and the immunogenicity results met the clinical expectations.